February 2017

Searching for the Key to Trastuzumab Cardiotoxicity in HER2+ Breast Cancer

March 10, 2017

Clinical Articles

Treatment with trastuzumab (Herceptin) has shown such a benefit in the treatment of patients with HER2-positive breast cancer that it is now the standard of care despite its association with cardiotoxicity. As such, researchers have taken to searching for ways to lessen or prevent the incidence of cardiac events in trials with trastuzumab.

Rare Cardiotoxicity Effects Founds With Checkpoint Inhibitors in Melanoma

March 16, 2017

Clinical Articles

As the oncology community adapts to using immunotherapy agents more frequently in cancer treatments, the fear over immune-related adverse events (irAEs) prevents many clinicians from fully trusting immunotherapies.

Immunotherapy Making Its Mark on Head and Neck Cancer

March 22, 2017

Clinical Articles

Following the approval of 2 immunotherapy agents, pembrolizumab and nivolumab for the treatment of patients with head and neck cancer over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC.

Globetrotting Head and Neck Cancer Show Hits 8 Countries

March 22, 2017

Clinical Articles

The International Federation of Head and Neck Oncologic Societies recently completed its fourth tour, with 8 experts in the field of head and neck oncology traveling to 8 countries over a month to offer continuing medical education courses on treatment paradigms and surgical techniques in head and neck cancer across the world.

Mutational Load is Only One Piece of the Immunotherapy Puzzle

March 22, 2017

Clinical Articles

As immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will respond better to immunotherapy. Mutational load is one such biomarker that appears to have an impact on response to immunotherapy, particularly for checkpoint inhibitors.

Pharmacy Benefit Managers Fees Drive Up Drug Costs

March 22, 2017

Clinical Articles

A new trend in the way pharmacy benefit managers are collecting fees from pharmacy providers is driving up drug costs, gouging point-of-sale pharmacy operations, and playing havoc with spending at Centers for Medicare & Medicaid Services.